Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Show more

1111 Kane Concourse, Bay Harbor Islands, FL, 33154, United States

Biotechnology

Healthcare

Market Cap

1.571M

52 Wk Range

$0.15 - $0.97

Previous Close

$0.53

Open

$0.22

Volume

10,898

Day Range

$0.22 - $0.48

Enterprise Value

-1.109M

Cash

2.855M

Avg Qtr Burn

-854K

Insider Ownership

20.64%

Institutional Own.

7.02%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IV Tramadol Details Pain, Post operative acute pain	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BAER-101 Details Anxiety Disorders, Epilepsy	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AJ201 Details Huntington's disease, Spinal and bulbar muscular atrophy , Spinocerebellar Ataxia, Kennedy's Disease	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.